Latest news
Latest news
Major sectors in leveraged loans are trading down, making shrewd credit selection vital
Deal is one of the tightest prints this year and is the second European CLO solely arranged by Mizuho
Debut manager is launching a CLO platform building on leveraged loan market experience
More articles
More articles
-
The US CLO new issue market is rolling headlong into the dog days of summer, with Prudential Fixed Income and Credit Suisse Asset Management each pricing new deals.
-
Valeant moved to reassure its investors on Thursday over the company’s future after former CEO Michael Pearson sold off a large portion of his shares, causing a drop in the value of the stock on Thursday morning. -
Invesco and Soundpoint Capital Management have each priced CLOs this week ahead of a wave of issuance from big name managers that is expected to hit the primary market before the August lull.
-
US CLO spreads have made a comeback as investors alter their thinking on the impact of the last month's UK referendum on EU membership.
-
Investors in Europe and the US are looking at the US middle market CLO sector as a hedge against macroeconomic uncertainty in the wake of Brexit.
-
Scandinavian asset management firm Accunia priced its debut CLO on Tuesday, as other CLO managers switch from sponsor structures to originator risk retention models to account for the uncertainty over future UK passporting rights.
-
Weakness in the Italian commercial property market will hit bondholders in Natixis’ legacy Infinity 2006-1 “Classico” synthetic CMBS deal, after a listed Italian property fund defaulted on a €378m loan backing the bulk of the deal.
-
UK CLO managers who fund CLO risk retention through the sponsor route are scrambling to set up alternative structures in the wake of the British referendum result, which could see the end of passporting rules and threaten the ability of UK based managers to run European CLOs.
-
Valeant Pharmaceuticals is facing an important test in its ability to reverse its fortunes this summer, as CLO market players say that the fate of the Canadian pharmaceutical giant will have a substantial effect on the sector.
